ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.
Crescens Tiu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.